US Patent:
20220267442, Aug 25, 2022
Inventors:
- New York NY, US
Shun Li - New York NY, US
Ming Liu - New York NY, US
International Classification:
C07K 16/28
C07K 14/71
A61P 35/00
A61K 45/06
A61K 38/17
A61K 39/395
C07K 16/24
Abstract:
The present disclosure provides fusion proteins that specifically inhibit transforming growth factor-β (TGF-β) signaling in CD4+ helper T cells, and engineered CD4+ helper T cells that are deficient in TGF-β signaling, to counteract tumor-induced immune tolerance and promote anti-tumor immunity. The fusion proteins and engineered CD4+ helper T cells of the present technology are useful in methods for treating cancer, and enhancing the efficacy of other therapeutic agents against refractory cancer cells.
